Placebo Controlled Comparative Study of SJP-0130 in Primary Open Angle Glaucoma or Ocular Hypertention patients

SJP-0130 Phase 2 -Placebo Controlled Parallel Group Study in Primary Open Angle Glaucoma or Ocular Hypertention patients-

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210584

Enrollment

Registered

2022-02-07

Start date

2022-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma / Oular hypertension

Interventions

Administration of SJP-0130 or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Aged 20 years or older and less than 75 years at the time of the informed consent - Male or non-childbearing potential female patients - Have been diagnosed with primary open angle glaucoma or ocular hypertension - Meet the other protocol-specified inclusion criteria

Exclusion criteria

Exclusion criteria: - Received treatment of glaucoma other than eye drops in eye - Received surgery or laser therapy in eye - Have ophthalmic disease other than primary open angle glaucoma or ocular hypertention - Have known history of hypersensitivity or serious adverse reaction to any of the study drug ingredients - Have advanced visual field disorder - Have eye abnomalitites that interfere with accurate measurement of ocular pressure - Have judged that it is inappropriate to participate in this study by investigator - Meet the other protocol-specified exclusion criteria

Design outcomes

Primary

Measure	Time frame
Efficacy and safety	—

Contacts

Public Contactdivision Clinical

Senju Pharmaceutical Co., Ltd.

senju-clinicaltrials@senju.co.jp+81-78-777-1018

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026